Clinical

Articles

Two recent studies demonstrate that pirfenidone (Esbriet, Genentech) prolongs life expectancy by 2.47 years for IPF patients and that Esbriet and nintedanib (Ofev, Boehringer Ingelheim) reduce the decline in lung function.

Drug prolongs IPF life expectancy: Study

Pete Mulliner, an IPF patient and ambassador for the Pulmonary Fibrosis Foundation, discusses how he believes physicians should treat patients who have been recently diagnosed with IPF.

How to help IPF patients – from their point of view

Boehringer Ingelheim recently began a clinical trial to assess the safety and tolerability of adding on pirfenidone to Ofev (nintedanib) for idiopathic pulmonary fibrosis patients.

IPF drug to be tested with add-on therapy

The Pulmonary Fibrosis Foundation and Boehringer Ingelheim’s new five-year partnership, aims to raise awareness of pulmonary fibrosis, provide disease education and advance care and funding research for the PF community

Manufacturer-Foundation partnership to increase PF research

Most idiopathic pulmonary fibrosis patients have considerably impaired lung function and gastroesophageal reflux disease is the most common co-morbidity, according to initial results from the IPF-PRO Registry.

Top 5 findings about IPF patients

A new survey of over 400 pulmonologists from 10 countries found that 88% of pulmonologists believe a delay in the diagnosis of idiopathic pulmonary fibrosis negatively impacts patients.

Doctors understand patients’ IPF concerns

Janet Woodcock, MD, director of the Center for Drug Evaluation and Research at the FDA, will speak about the future of drug development in pulmonary fibrosis during the PFF Summit 2015: From Bench to Bedside conference, November 12-14 in Washington D.C.

Woodcock to keynote PFF Summit

When two new treatments for idiopathic pulmonary fibrosis (IPF) were approved by FDA last year, there was not much data available on the drugs in patient populations.

Top 3 new findings on nintedanib to treat IPF

Here are 3 major concerns patients with IPF should be aware of, according to research from Carlo Vancheri that appeared in a recent issue of Sarcoidosis Vasculitis and Diffuse Lung Diseases.

3 top concerns with IPF and comorbidities [SLIDESHOW]

Pulmonary fibrosis (PF) organizations and healthcare providers are lauding the update of the Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis, which was last updated in 2011.